Liesbeth Viaene

p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease

Björn Meijers, Kathleen Claes, Bert Bammens et al. · Clinical Journal of the American Society of Nephrology · 2010 · 309 citations

Medicine, Nephrology, Dialysis +14

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Sclerostin: Another Vascular Calcification Inhibitor?

Kathleen Claes, Liesbeth Viaene, Sam Heye et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 163 citations

Medicine, Endocrinology, Nephrology +13

Albumin is the main plasma binding protein for indoxyl sulfate and <i>p</i>‐cresyl sulfate

Liesbeth Viaene, Pieter Annaert, Henriëtte de Loor et al. · Biopharmaceutics & Drug Disposition · 2013 · 119 citations · Full text

Medicine, Biochemistry, Nephrology +12

Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?

Liesbeth Viaene, Geert J. Behets, Kathleen Claes et al. · Nephrology Dialysis Transplantation · 2013 · 116 citations

Medicine, Nephrology, Bone Metabolism +15